Vertex (VRTX) EVP Tatsis logs 10b5-1 sale and tax share disposal

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Ourania Tatsis, EVP and Chief Regulatory & Quality Officer, reported two transactions in Vertex common stock. She completed an open-market sale of 260 shares at $486.35 per share under a company-approved Rule 10b5-1 trading plan. In a separate transaction, she disposed of 1,627 shares at $485.11 per share to cover tax obligations. After these transactions, she directly holds 46,763 shares of Vertex common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tatsis Ourania

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Reg. & Quality Off.

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		F		1,627	D	$485.11	47,023	D
Common Stock	02/25/2026		S(1)		260	D	$486.35	46,763	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Vertex (VRTX) EVP Ourania Tatsis report?

EVP Ourania Tatsis reported two transactions in Vertex common stock: an open-market sale of 260 shares and a separate 1,627-share disposal to cover tax obligations related to equity compensation, both at prices around $485 per share.

At what prices did Vertex (VRTX) executive Ourania Tatsis transact her shares?

Ourania Tatsis sold 260 Vertex shares at $486.35 each and disposed of 1,627 shares at $485.11 each to satisfy tax obligations, reflecting transaction prices in a narrow range just under $487 per share.

How many Vertex (VRTX) shares does Ourania Tatsis own after these Form 4 transactions?

After the reported transactions, EVP Ourania Tatsis directly owns 46,763 shares of Vertex common stock. This figure reflects her remaining direct holdings following both the 260-share open-market sale and the 1,627-share tax-withholding disposition.

Was the Vertex (VRTX) insider sale by Ourania Tatsis under a Rule 10b5-1 plan?

Yes. The Form 4 notes the transaction was made under a company-approved Rule 10b5-1 trading plan. Such plans pre-schedule trades, aiming to separate routine portfolio management from short-term market information influences for insiders.

What does the Form 4 tax-withholding transaction mean for Vertex (VRTX) shares?

The 1,627-share transaction is labeled as a tax-withholding disposition, meaning shares were delivered to satisfy tax liabilities from equity compensation, rather than representing a discretionary open-market sale decision by the executive.